Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe 2.5mg dose of Mounjaro is not designed to produce significant weight loss on its own. It is a tolerability dose — its job is to let your body adjust to tirzepatide before the real treatment work begins at higher strengths. Most people move up from 2.5mg after four weeks, guided by their prescriber. These are prescription-only medicines; a clinician assesses whether they are suitable for you before any treatment starts.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide slows gastric emptying and dials down appetite through two gut-hormone receptors simultaneously. That mechanism is also what causes nausea, indigestion and loose stools in some people, particularly in the first few weeks. Starting at a low dose gives your digestive system time to adapt before the dose climbs to levels where meaningful appetite suppression sets in.
Think of 2.5mg as the settling-in period rather than the treatment itself. The 2.5mg dose carries a Black Triangle (▼) status alongside the rest of the Mounjaro range, meaning the MHRA continues to monitor it closely as a relatively new medicine, worth knowing, even if it changes nothing about how you take it.
Some people do notice a small reduction in appetite or a few pounds lost at this stage. That is a bonus, not the goal. If your scale barely moves in weeks one to four, that is expected, not a sign the medicine is failing you.
Tolerating 2.5mg without side effects is actually the green light to move up, not a reason to stay. The NHS medicines page for tirzepatide outlines that the dose is titrated (increased in steps) because therapeutic effect and tolerability both improve as the body acclimates over time.
Staying at 2.5mg longer than the intended four-week starter period is unlikely to produce the outcomes that clinical trials demonstrated. SURMOUNT-1, which involved 2,539 adults, showed that statistically meaningful weight reduction built progressively with each dose increase, reaching its peak at 10mg and 15mg. A quick way to check where you are in the schedule: look at the date on your first pen's packaging and count four weeks forward, if that date has passed and you haven't had a prescriber review, it is worth making contact.
If you are curious about whether 5mg is enough once you move up, the same principle applies, the prescriber reviews your response before deciding whether to titrate further.
The starter dose tends to produce the mildest side-effect profile of the entire schedule, which is precisely its purpose. Nausea, constipation, reduced appetite and occasional fatigue are the most commonly reported effects at this stage. They are generally mild, and for many people they settle within the first two weeks.
That said, some people do find even 2.5mg uncomfortable. Gastrointestinal symptoms (loose stools, reflux, burping) can appear at any dose. Eating smaller portions and avoiding high-fat meals at the start helps many people manage this. If symptoms are severe or persistent, contact your prescriber rather than pushing through; very occasionally a slower titration is the right clinical call.
For symptoms that feel more serious (severe, persistent stomach pain that reaches the back, signs of an allergic reaction, or anything that worries you) seek medical help promptly rather than waiting for your next check-in. The MHRA's Yellow Card scheme is also there to report any suspected side effects, at any dose.
Most people report noticeable appetite reduction and early weight change somewhere between week four and week twelve, as the dose climbs above the starter level. If you want to understand what to expect as you move from the 2.5mg starter to 5mg, there is a dedicated page covering that specific step in detail.
Weight loss is rarely linear. Weeks where the number barely shifts can follow weeks of faster progress, and the pace often slows temporarily after each dose increase while the body adjusts. Progress at the 2.5mg stage should not be used as the benchmark for the treatment overall.
The full Mounjaro overview covers how results build across the dose schedule. If you are considering whether this treatment is right for you, the weight-loss treatment overview sets out the options clearly. For a broader look at the 2.5mg pen itself (how it works, how to use it and what to expect) there is a dedicated page that goes into the practical detail.
At nume, every consultation is read by a GPhC-registered Independent Prescriber, not software. If you have already been on Mounjaro elsewhere and want to continue, our clinical team reviews transfer patients with the same rigour as new starts. Start your free consultation and a prescriber will assess your situation the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.